Compare DFLI & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DFLI | ALLR |
|---|---|---|
| Founded | 2020 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.8M | 21.5M |
| IPO Year | 2021 | 2021 |
| Metric | DFLI | ALLR |
|---|---|---|
| Price | $0.88 | $1.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $3.25 | ★ $9.75 |
| AVG Volume (30 Days) | ★ 243.7K | 85.7K |
| Earning Date | 05-14-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $58,630,000.00 | $320,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $51.17 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 15.77 | N/A |
| 52 Week Low | $0.28 | $0.77 |
| 52 Week High | $5.15 | $1.84 |
| Indicator | DFLI | ALLR |
|---|---|---|
| Relative Strength Index (RSI) | 28.61 | 36.29 |
| Support Level | $0.41 | $1.01 |
| Resistance Level | $1.18 | $1.27 |
| Average True Range (ATR) | 0.07 | 0.10 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 21.36 | 18.75 |
Dragonfly Energy Holdings Corp is engaged in the design, assembly, and sale of lithium-ion batteries, mainly lithium iron phosphate (LFP) batteries, for applications in recreational vehicles, marine, industrial, and other markets. The company operates through two segments: direct-to-consumer (DTC), which sells Battle Born branded batteries, and OEM, which supplies Dragonfly branded batteries to original equipment manufacturers.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.